Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

Jaap Verweij; Paolo G. Casali; Dusan Kotasek; Axel Le Cesne; Peter Reichard; Ian R. Judson; R. Issels; Allan T. van Oosterom; Martine Van Glabbeke; Jean Yves Blay

doi:10.1016/j.ejca.2007.01.018

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

Jaap Verweij, Paolo G. Casali, Dusan Kotasek, Axel Le Cesne, Peter Reichard, Ian R. Judson, R. Issels, Allan T. van Oosterom, Martine Van Glabbeke, Jean Yves Blay

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

83 Citations (Scopus)

Résumé

Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400 mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity.

langue originale	Anglais
Pages (de - à)	974-978
Nombre de pages	5
journal	European Journal of Cancer
Volume	43
Numéro de publication	6
Les DOIs	https://doi.org/10.1016/j.ejca.2007.01.018
état	Publié - 1 avr. 2007

Accès au document

10.1016/j.ejca.2007.01.018

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Verweij, J., Casali, P. G., Kotasek, D., Le Cesne, A., Reichard, P., Judson, I. R., Issels, R., van Oosterom, A. T., Van Glabbeke, M., & Blay, J. Y. (2007). Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005. European Journal of Cancer, 43(6), 974-978. https://doi.org/10.1016/j.ejca.2007.01.018

@article{889a9e8b67334f34af52b74605e7f704,

title = "Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005",

abstract = "Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400 mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity.",

keywords = "Cardiotoxicity, GIST, Imatinib",

author = "Jaap Verweij and Casali, {Paolo G.} and Dusan Kotasek and {Le Cesne}, Axel and Peter Reichard and Judson, {Ian R.} and R. Issels and {van Oosterom}, {Allan T.} and {Van Glabbeke}, Martine and Blay, {Jean Yves}",

note = "Funding Information: This study was supported by an unrestricted grant from Novartis Oncology. Novartis was not involved in the writing of this manuscript, but has reviewed its content prior to submission Funding Information: This publication was supported by Grant(s) number 2U10 CA11488-29 (through 5U10 CA11488-34) from the National Cancer Institute (Bethesda, MD, USA). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. ",

year = "2007",

month = apr,

day = "1",

doi = "10.1016/j.ejca.2007.01.018",

language = "English",

volume = "43",

pages = "974--978",

journal = "European Journal of Cancer",

issn = "0959-8049",

number = "6",

}

Verweij, J, Casali, PG, Kotasek, D, Le Cesne, A, Reichard, P, Judson, IR, Issels, R, van Oosterom, AT, Van Glabbeke, M & Blay, JY 2007, 'Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005', European Journal of Cancer, VOL. 43, Numéro 6, p. 974-978. https://doi.org/10.1016/j.ejca.2007.01.018

TY - JOUR

T1 - Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients

T2 - Analyis of EORTC-ISG-AGITG study 62005

AU - Verweij, Jaap

AU - Casali, Paolo G.

AU - Kotasek, Dusan

AU - Le Cesne, Axel

AU - Reichard, Peter

AU - Judson, Ian R.

AU - Issels, R.

AU - van Oosterom, Allan T.

AU - Van Glabbeke, Martine

AU - Blay, Jean Yves

N1 - Funding Information: This study was supported by an unrestricted grant from Novartis Oncology. Novartis was not involved in the writing of this manuscript, but has reviewed its content prior to submission Funding Information: This publication was supported by Grant(s) number 2U10 CA11488-29 (through 5U10 CA11488-34) from the National Cancer Institute (Bethesda, MD, USA). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400 mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity.

AB - Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400 mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity.

KW - Cardiotoxicity

KW - GIST

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=33947722204&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2007.01.018

DO - 10.1016/j.ejca.2007.01.018

M3 - Article

C2 - 17336514

AN - SCOPUS:33947722204

SN - 0959-8049

VL - 43

SP - 974

EP - 978

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 6

ER -